Utility of Pre-Hematopoietic Cell Transplantation Sinus CT Screening in Children and Adolescents

Article Figures & Data

Table 1:

Patient characteristics

Characteristics
No.	100
Male	60
Female	40
Age (mean) (yr)	11.9 ± 5.5
Primary diagnosis (No.) (%)
Hematologic malignancy	65, 65%
Acute myeloid leukemia	34, 34%
Acute lymphoblastic leukemia	17, 17%
Hodgkin lymphoma	8, 8%
Myelodysplastic syndrome	5, 5%
Anaplastic large-cell lymphoma	1, 1%
Hematologic disorder	5, 5%
Severe aplastic anemia	3, 3%
Sickle cell disease	2, 2%
Solid tumor	28, 28%
Neuroblastoma	15, 15%
Ewing sarcoma	9, 9%
Germ cell tumor	3, 3%
Desmoplastic small round cell tumor	1, 1%
Immune disorder	2, 2%
Severe combined immunodeficiency	1. 1%
Wiskott-Aldrich syndrome	1, 1%
Transplant donor (No.) (%)
Allogenic	66, 66%
Autologous	34, 34%
Disease status at transplantation (No.) (%)
Complete remission	82, 82%
Active disease	18, 18%
T-cell depletion (No.) (%)	2, 2%
GVHD II–IV (No.) (%)	15, 15%

Table 2:

Pretransplantation sinus CT Lund-Mackay scores, sinonasal symptoms, and management

	No. (Frequency)	Pre-HCT Lund-Mackay Score (Mean)	P Value
All at screening	100 (100%)	3.48 ± 4.58
No symptoms at screening	82 (82%)	2.48 ± 3.51	<.001
Symptoms at screening	18 (18%)	8.07 ± 6.00
With symptoms, received antibiotics	5 (28%)	12.80 ± 5.72	.058
With symptoms, no antibiotics	13 (72%)	6.25 ± 5.25

Table 3:

Pre-HCT Lund-Mackay scores versus posttransplantation sinus outcomes

	No. (Frequency)	Pre-HCT Lund-Mackay Score (Mean)	P Value
All at screening	100 (100%)	3.48 ± 4.58
No post-HCT symptoms	79 (79%)	3.38 ± 4.49	.47
Post-HCT symptoms	21 (21%)	3.86 ± 5.00
Post-HCT symptoms, IFRS	2 (9.5%)	4.00 ± 4.24	.58
Post-HCT symptoms, no IFRS	19 (90.5%)	3.84 ± 5.17

Table 4:

Clinical findings at screening for patients who did and did not develop IFRS after transplantation

	All at Pre-HCT Screen	No Post-HCT IFRS	Post-HCT IFRS	P Value
No.	100	98	2
ENT risk estimate (No.) (frequency)
At risk	29 (29%)	28 (29%)	1 (50%)	.61
Low risk	67 (67%)	62 (63%)	1 (50%)
Not evaluated	4 (4%)	8 (8%)	0
ANC at imaging (mean)	2510 ± 5568	2524 ± 5622	1800 ± 1697	.86
Transplant donor (No.) (frequency)
Allogenic	66 (66%)	65 (66%)	1 (50%)	1
Autologous	34 (34%)	33 (34%)	1 (50%)
Disease status at transplantation (No.) (frequency)
Complete remission	82 (82%)	80 (80%)	2 (100%)	1
Active disease	18 (18%)	18 (18%)
T-cell depletion (No.) (frequency)	2 (2%)	2 (2%)	0	1
GVHD II–IV (No.) (frequency)	15 (15%)	15 (15%)	0	1